Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

14 October 2011

AIDS Treatment is a Good Value!

via PLoS ONE and Results for Development Institute, by Stephen Resch1, Eline Korenromp, John Stover, Matthew Blakley, Carleigh Krubiner, Kira Thorien, Robert Hecht, Rifat Atun

Despite the remarkable scale-up of AIDS treatment and prevention programs in low and middle income countries in recent years, each year two million people die from AIDS (most without ever having received antiretrovirals ART) and 2.7 million are newly infected by HIV.

A study released in PLoS ONE, co-authored by a group from Results for Development Institute and the Global Fund, argues that large scale investment in ART in low and middle income countries yields a stream of economic benefits that is likely to offset substantially or exceed the costs of delivering AIDS treatment to millions of patients in these countries.

The study, The Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries, is one of the first efforts to look systematically at the expected economic benefits (returns) to large scale investment in AIDS treatment.

The study models three streams of future economic benefits accruing to the roughly 3 million persons who were on Global Fund supported treatment in 2010 in 98 countries around the world: (1) restored labor productivity amongst workers with AIDS, (2) orphan care expenditures avoided because parents remain alive on ART, and (3) delayed end-of-life care costs associated with death from AIDS. These streams of economic benefits were selected because they offset the cost of treatment over short time horizons and therefore may be especially salient to policy-makers concerned with health budgets, household economic stability and societal-level economic growth.

Using recent ART prices and program costs, the study estimates that the discounted resource needs required for this cohort of patients over the coming decade are US$14.2 billion.This investment is expected to save 18.5 million life years and return $12-34 billion. This yields economic benefits from ART ranging from 80% to 290% of program costs

Read the rest.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

No comments:

Post a Comment